April 4, 2022
We did not observe a statistically significant change in the ASIRs of childhood cancer during the first 9 months of the COVID-19 pandemic in Canada compared with the period before the pandemic. Moreover, enrolment in clinical trials remained stable, and we did not observe an increase in the proportion of patients with metastatic disease or early mortality. Although these results are reassuring, continued surveillance is necessary to ascertain potential long-term negative effects of the COVID-19 pandemic among children with cancer.